Metoclopramide Hydrochloride Syri

Metoclopramide Hydrochloride, the active ingredient in Metoclopramide Hydrochloride Syri, is a dopamine D2 receptor antagonist presented as an oral formulation for oral use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and aid gastro‑oesophageal reflux disease management.

GNH USA supplies Metoclopramide Hydrochloride Syri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide Hydrochloride is indicated for conditions affecting the gastrointestinal tract and the chemoreceptor trigger zone.

Nausea and vomiting: reduces frequency and severity of episodes in postoperative, chemotherapy‑induced, and other causes. Gastroparesis: enhances gastric motility to improve stomach emptying and symptom control. Gastro‑oesophageal reflux disease (GERD): supports lower esophageal sphincter tone and reduces reflux episodes.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness or fatigue - Restlessness or akathisia - Diarrhea, headache, or dizziness

Serious or Rare Side Effects: - Tardive dyskinesia (involuntary movements) - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Seizures - Anaphylactic or severe allergic reactions - Cardiac arrhythmias

Before initiating therapy, clinicians should consider several safety aspects.

Assess renal function: adjust use in severe renal impairment. Monitor for extrapyramidal symptoms: observe for involuntary movements. Avoid in patients with known hypersensitivity: discontinue if reaction occurs. Use caution in pregnancy: limited data, weigh benefits versus risks. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Metoclopramide can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticholinergic agents: may reduce prokinetic effect. - CYP2D6 inhibitors (e.g., fluoxetine): increase plasma levels. - Other dopamine antagonists: additive risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely): - Opioids: may enhance nausea control. - Alcohol: may increase central nervous system depression. - MAO inhibitors: potential for hypertensive crisis (rare).